Inhibition of the synthesis of eicosanoid-like substances in a human oral cancer cell line by interferon-gamma and eicosapentaenoic acid.
The objectives were to examine the production of eicosanoids in a Chinese human oral cancer cell line (OEC-M1) and to test the effects of interferon-gamma (IFN-gamma), eicosapentaenoic acid (EPA) and enzyme inhibitors on this biosynthesis. The eicosanoids were identified by reverse phase-high performance liquid chromatography. Two predominant peaks appeared in the chromatograms. One compound (P-1) was identified by ultraviolet absorption at a lambda(max) of 278nm with shoulders at 272 and 284nm. The other compound (P-2) was identified by ultraviolet absorption at a lambda(max) of 284 nm with shoulders at 278 and 290 nm. The production of P- was significantly inhibited by the addition of IFN-gamma (200 and 400 U/ml), and EPA (10 to 40 microM). It was only partially inhibited (p < 0.05) by indomethacin (INDO) (0.5 and 1 microM), nordihydroguaiaretic acid (NDGA) (30 and 60 microM/ml), and eicosa-5,8,11,14-tetraynoic acid (ETYA) (20-60 microM). It was almost completely inhibited by indomethacin (2 and 3 microM), and dexamethasone (0.6 and 6 microM). The production of P-2 was almost completely inhibited by IFN-gamma (200 and 400 U/ml), and partially inhibited (p < 0.05) by EPA (10 and 20 microM), NDGA (30 and 60 microM), ETYA (20 and 40 microM), dexamethasone (0.6 and 6 microM). The production of both peaks was significantly reduced by excluding arachidonic acid (AA), and almost completely inhibited by heating at 100 degrees C for 10 min during incubation. These results demonstrate that two eicosanoid-like compounds are synthesized by the OEC-M cell line and that their production can be modulated by IFN-gamma, EPA, indomethacin, NDGA, ETYA, and dexamethasone.
Meng
C L
CL
Department of Dentistry, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Yang
C Y
CY
Shen
K L
KL
Wong
P Y
PY
Lee
H K
HK
D015117:5,8,11,14-Eicosatetraynoic Acid / Q000494:pharmacology; D000704:Analysis of Variance; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors; D002277:Carcinoma / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D015777:Eicosanoids / Q000032:analysis / Q000037:antagonists & inhibitors*; D015118:Eicosapentaenoic Acid / Q000494:pharmacology*; D005887:Gingival Neoplasms / Q000378:metabolism*; D005938:Glucocorticoids / Q000494:pharmacology; D006358:Hot Temperature; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology*; D009637:Masoprocol / Q000494:pharmacology; D013056:Spectrophotometry, Ultraviolet; D014407:Tumor Cells, Cultured
D001095:Arachidonic Acids; D016861:Cyclooxygenase Inhibitors; D015777:Eicosanoids; D005938:Glucocorticoids; D015117:5,8,11,14-Eicosatetraynoic Acid; D009637:Masoprocol; D003907:Dexamethasone; D007371:Interferon-gamma; D015118:Eicosapentaenoic Acid; D007213:Indomethacin